Bevacizumab, whose correct name is bevacizumab, can be continued after 3 years of use and discontinued only if the disease progresses or is not tolerated. Bevacizumab is mainly used for the treatment of advanced metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer. It is recommended for long-term use to effectively improve the condition and significantly prolong the survival of patients. It is recommended to continue treatment with this product until the disease progresses or until an adverse reaction that is not tolerated by the patient occurs. Common adverse reactions to this product include fever, decreased blood counts, hypertension, diarrhea, nausea, vomiting, and fatigue, and it is contraindicated in those who are allergic to this product. It is recommended that the physician to assess the condition before deciding whether to continue to use the drug, do not blindly use and stop the drug, during the use of any discomfort is recommended to consult a doctor in order to avoid delays in the condition.